Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Arcadia Biosciences ( (RKDA) ).
On August 26, 2025, Arcadia Biosciences‘ CFO, Mark Kawakami, announced his resignation effective September 12, 2025, with no disagreements cited as the reason. Thomas J. Schaefer, the company’s President and CEO, will assume the role of Interim CFO. Additionally, Arcadia is involved in a proposed all-stock transaction with Roosevelt Resources, with plans to issue shares in exchange for Roosevelt’s equity interests, pending regulatory approvals.
The most recent analyst rating on (RKDA) stock is a Hold with a $4.50 price target. To see the full list of analyst forecasts on Arcadia Biosciences stock, see the RKDA Stock Forecast page.
Spark’s Take on RKDA Stock
According to Spark, TipRanks’ AI Analyst, RKDA is a Neutral.
Arcadia Biosciences’ overall stock score is primarily impacted by its financial challenges, including declining revenue and profitability issues. However, positive developments in the earnings call, such as Zola’s revenue growth and strategic monetization efforts, provide some optimism. Technical analysis and valuation metrics indicate caution, with mixed signals and a negative P/E ratio.
To see Spark’s full report on RKDA stock, click here.
More about Arcadia Biosciences
Arcadia Biosciences operates in the agricultural biotechnology industry, focusing on developing and commercializing products that enhance the quality and nutritional value of crops. The company is known for its innovative solutions aimed at improving crop productivity and sustainability.
Average Trading Volume: 10,980
Technical Sentiment Signal: Sell
Current Market Cap: $5.26M
Learn more about RKDA stock on TipRanks’ Stock Analysis page.